Target Price | $17.00 |
Price | $3.43 |
Potential |
395.63%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Checkpoint Therapeutics, Inc. 2025 .
The average Checkpoint Therapeutics, Inc. target price is $17.00.
This is
395.63%
register free of charge
$27.00
687.17%
register free of charge
$4.00
16.62%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend Checkpoint Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Checkpoint Therapeutics, Inc. stock has an average upside potential 2025 of
395.63%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 0.10 | 0.02 |
47.37% | 76.00% | |
EBITDA Margin | -52,150.00% | -159,583.33% |
69.87% | 206.01% | |
Net Margin | -126,866.00% | -166,025.00% |
25.77% | 30.87% |
3 Analysts have issued a sales forecast Checkpoint Therapeutics, Inc. 2024 . The average Checkpoint Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Checkpoint Therapeutics, Inc. 2024 . The average Checkpoint Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-52.2m | 10.59% |
---|---|---|
2024 |
$-38.3m
26.56%
Unlock
|
2023 | -52,150.00% | 69.87% |
---|---|---|
2024 |
-159,583.33%
206.01%
Unlock
|
1 Analyst has issued a net profit forecast Checkpoint Therapeutics, Inc. 2024 . The average Checkpoint Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.77 | -0.87 |
60.93% | 68.59% | |
P/E | negative | |
EV/Sales | 6,783.33 |
1 Analysts have issued a Checkpoint Therapeutics, Inc. forecast for earnings per share. The average Checkpoint Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Checkpoint Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Checkpoint Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.